1. Home
  2. JG vs TVRD Comparison

JG vs TVRD Comparison

Compare JG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Mobile Limited

JG

Aurora Mobile Limited

HOLD

Current Price

$6.83

Market Cap

40.6M

Sector

Technology

ML Signal

HOLD

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$3.02

Market Cap

36.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JG
TVRD
Founded
2012
2017
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.6M
36.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
JG
TVRD
Price
$6.83
$3.02
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.67
AVG Volume (30 Days)
951.0
46.3K
Earning Date
03-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.85
$2.81
52 Week High
$12.74
$43.65

Technical Indicators

Market Signals
Indicator
JG
TVRD
Relative Strength Index (RSI) 43.77 31.52
Support Level $6.80 N/A
Resistance Level $6.97 $4.52
Average True Range (ATR) 0.28 0.27
MACD -0.04 -0.05
Stochastic Oscillator 3.17 17.07

Price Performance

Historical Comparison
JG
TVRD

About JG Aurora Mobile Limited

Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: